Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 101

1.

Use of biomarkers and imaging to assess pathophysiology, mechanisms of action and target engagement.

Hampel H, Lista S.

J Nutr Health Aging. 2013 Jan;17(1):54-63. doi: 10.1007/s12603-013-0003-1.

PMID:
23299381
2.

Development of biomarkers to chart all Alzheimer's disease stages: the royal road to cutting the therapeutic Gordian Knot.

Hampel H, Lista S, Khachaturian ZS.

Alzheimers Dement. 2012 Jul;8(4):312-36. doi: 10.1016/j.jalz.2012.05.2116. Review.

PMID:
22748938
3.

Perspective on future role of biological markers in clinical therapy trials of Alzheimer's disease: a long-range point of view beyond 2020.

Hampel H, Lista S, Teipel SJ, Garaci F, Nisticò R, Blennow K, Zetterberg H, Bertram L, Duyckaerts C, Bakardjian H, Drzezga A, Colliot O, Epelbaum S, Broich K, Lehéricy S, Brice A, Khachaturian ZS, Aisen PS, Dubois B.

Biochem Pharmacol. 2014 Apr 15;88(4):426-49. doi: 10.1016/j.bcp.2013.11.009. Epub 2013 Nov 22. Review.

PMID:
24275164
4.

Paths to Alzheimer's disease prevention: from modifiable risk factors to biomarker enrichment strategies.

Lista S, Dubois B, Hampel H.

J Nutr Health Aging. 2015 Feb;19(2):154-63. doi: 10.1007/s12603-014-0515-3. Review.

PMID:
25651440
5.

Advances in the therapy of Alzheimer's disease: targeting amyloid beta and tau and perspectives for the future.

Hampel H, Schneider LS, Giacobini E, Kivipelto M, Sindi S, Dubois B, Broich K, Nisticò R, Aisen PS, Lista S.

Expert Rev Neurother. 2015 Jan;15(1):83-105. doi: 10.1586/14737175.2015.995637. Epub 2014 Dec 24. Review.

PMID:
25537424
6.

The future of Alzheimer's disease: the next 10 years.

Hampel H, Prvulovic D, Teipel S, Jessen F, Luckhaus C, Frölich L, Riepe MW, Dodel R, Leyhe T, Bertram L, Hoffmann W, Faltraco F; German Task Force on Alzheimer's Disease (GTF-AD).

Prog Neurobiol. 2011 Dec;95(4):718-28. doi: 10.1016/j.pneurobio.2011.11.008. Epub 2011 Nov 22. Review.

PMID:
22137045
7.

Biomarkers for Alzheimer's disease: academic, industry and regulatory perspectives.

Hampel H, Frank R, Broich K, Teipel SJ, Katz RG, Hardy J, Herholz K, Bokde AL, Jessen F, Hoessler YC, Sanhai WR, Zetterberg H, Woodcock J, Blennow K.

Nat Rev Drug Discov. 2010 Jul;9(7):560-74. doi: 10.1038/nrd3115. Review.

PMID:
20592748
8.

The Road Ahead to Cure Alzheimer's Disease: Development of Biological Markers and Neuroimaging Methods for Prevention Trials Across all Stages and Target Populations.

Cavedo E, Lista S, Khachaturian Z, Aisen P, Amouyel P, Herholz K, Jack CR Jr, Sperling R, Cummings J, Blennow K, O'Bryant S, Frisoni GB, Khachaturian A, Kivipelto M, Klunk W, Broich K, Andrieu S, de Schotten MT, Mangin JF, Lammertsma AA, Johnson K, Teipel S, Drzezga A, Bokde A, Colliot O, Bakardjian H, Zetterberg H, Dubois B, Vellas B, Schneider LS, Hampel H.

J Prev Alzheimers Dis. 2014 Dec;1(3):181-202.

9.

Current insights into the pathophysiology of Alzheimer's disease: selecting targets for early therapeutic intervention.

Hampel H.

Int Psychogeriatr. 2012 Aug;24 Suppl 1:S10-7. doi: 10.1017/S1041610212000579. Review.

PMID:
22784422
10.

Potential neuroimaging biomarkers of pathologic brain changes in Mild Cognitive Impairment and Alzheimer's disease: a systematic review.

Ruan Q, D'Onofrio G, Sancarlo D, Bao Z, Greco A, Yu Z.

BMC Geriatr. 2016 May 16;16:104. doi: 10.1186/s12877-016-0281-7. Review.

11.

Cognitive and Brain Profiles Associated with Current Neuroimaging Biomarkers of Preclinical Alzheimer's Disease.

Besson FL, La Joie R, Doeuvre L, Gaubert M, Mézenge F, Egret S, Landeau B, Barré L, Abbas A, Ibazizene M, de La Sayette V, Desgranges B, Eustache F, Chételat G.

J Neurosci. 2015 Jul 22;35(29):10402-11. doi: 10.1523/JNEUROSCI.0150-15.2015.

12.

Neuroimaging and the search for a cure for Alzheimer disease.

Petrella JR.

Radiology. 2013 Dec;269(3):671-91. doi: 10.1148/radiol.13122503. Review.

PMID:
24261497
13.

Core candidate neurochemical and imaging biomarkers of Alzheimer's disease.

Hampel H, Bürger K, Teipel SJ, Bokde AL, Zetterberg H, Blennow K.

Alzheimers Dement. 2008 Jan;4(1):38-48. doi: 10.1016/j.jalz.2007.08.006. Epub 2007 Dec 21. Review.

PMID:
18631949
14.

Cerebrospinal fluid and plasma biomarkers in Alzheimer disease.

Blennow K, Hampel H, Weiner M, Zetterberg H.

Nat Rev Neurol. 2010 Mar;6(3):131-44. doi: 10.1038/nrneurol.2010.4. Epub 2010 Feb 16. Review.

PMID:
20157306
15.

Evolving Evidence for the Value of Neuroimaging Methods and Biological Markers in Subjects Categorized with Subjective Cognitive Decline.

Lista S, Molinuevo JL, Cavedo E, Rami L, Amouyel P, Teipel SJ, Garaci F, Toschi N, Habert MO, Blennow K, Zetterberg H, O'Bryant SE, Johnson L, Galluzzi S, Bokde AL, Broich K, Herholz K, Bakardjian H, Dubois B, Jessen F, Carrillo MC, Aisen PS, Hampel H.

J Alzheimers Dis. 2015 Sep 24;48 Suppl 1:S171-91. doi: 10.3233/JAD-150202. Review.

PMID:
26402088
16.

Biomarkers in amyloid-β immunotherapy trials in Alzheimer's disease.

Blennow K, Hampel H, Zetterberg H.

Neuropsychopharmacology. 2014 Jan;39(1):189-201. doi: 10.1038/npp.2013.154. Epub 2013 Jun 25. Review.

17.

CSF Aβ1-42 combined with neuroimaging biomarkers in the early detection, diagnosis and prediction of Alzheimer's disease.

Lista S, Garaci FG, Ewers M, Teipel S, Zetterberg H, Blennow K, Hampel H.

Alzheimers Dement. 2014 May;10(3):381-92. doi: 10.1016/j.jalz.2013.04.506. Epub 2013 Jul 11. Review.

PMID:
23850330
18.

The Alzheimer's Disease Neuroimaging Initiative: a review of papers published since its inception.

Weiner MW, Veitch DP, Aisen PS, Beckett LA, Cairns NJ, Green RC, Harvey D, Jack CR, Jagust W, Liu E, Morris JC, Petersen RC, Saykin AJ, Schmidt ME, Shaw L, Siuciak JA, Soares H, Toga AW, Trojanowski JQ; Alzheimer’s Disease Neuroimaging Initiative.

Alzheimers Dement. 2012 Feb;8(1 Suppl):S1-68. doi: 10.1016/j.jalz.2011.09.172. Epub 2011 Nov 2. Review.

19.

The Alzheimer's Disease Neuroimaging Initiative: a review of papers published since its inception.

Weiner MW, Veitch DP, Aisen PS, Beckett LA, Cairns NJ, Green RC, Harvey D, Jack CR, Jagust W, Liu E, Morris JC, Petersen RC, Saykin AJ, Schmidt ME, Shaw L, Shen L, Siuciak JA, Soares H, Toga AW, Trojanowski JQ; Alzheimer's Disease Neuroimaging Initiative.

Alzheimers Dement. 2013 Sep;9(5):e111-94. doi: 10.1016/j.jalz.2013.05.1769. Epub 2013 Aug 7. Review.

20.

Novel Statistically-Derived Composite Measures for Assessing the Efficacy of Disease-Modifying Therapies in Prodromal Alzheimer's Disease Trials: An AIBL Study.

Burnham SC, Raghavan N, Wilson W, Baker D, Ropacki MT, Novak G, Ames D, Ellis K, Martins RN, Maruff P, Masters CL, Romano G, Rowe CC, Savage G, Macaulay SL, Narayan VA; Alzheimer’s Disease Neuroimaging Initiative; AIBL Research Group.

J Alzheimers Dis. 2015;46(4):1079-89. doi: 10.3233/JAD-143015.

PMID:
26402634

Supplemental Content

Support Center